My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Alembic Pharmaceuticals Ltd Research Report - 07th Nov 2016

Pharmaceutical | Published on Nov 07th 2016


Alembic Pharmaceuticals posted sales of Rs872cr (vs. Rs1,008cr in 2QFY2016), a dip of 13.5% yoy, mainly on back of base effect. International business declined owing to lower contribution from Abilify. On the operating front, the gross margin is expected to come in at 72.5% (vs. 77.5% in 2QFY2016) and EBIDTA margin at 20.3% (vs. 37.2% in 2QFY2016). Consequently, the PAT is expected to come in at Rs120cr (vs. Rs289cr in 2QFY2016), a yoy dip of 58.5%. We maintain our Neutral rating on the stock.

Download Full Report


CMP 676
Target Price
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others12.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo